Your Health, We Care
Release date: 2024-08-26 10:17:13 Recommended: 536
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) gave a positive recommendation for the approval of toripalimab (brand name Loqtorzi). This medication is intended for the first-line treatment of patients with nasopharyngeal carcinoma and oesophageal squamous cell carcinoma.
Applicant: TMC Pharma (EU) Limited
Form: 240 mg concentrate for solution for infusion
Active Substance: Toripalimab (ATC code: L01FF13)
Mechanism: Toripalimab is a humanized monoclonal antibody that targets PD-1, a protein that, when activated, inhibits immune responses, including those against tumors. By blocking this pathway, toripalimab enhances the body's immune response against cancer cells.
Efficacy
Clinical studies have shown that Loqtorzi improves progression-free survival in patients with locally advanced nasopharyngeal carcinoma and advanced or metastatic oesophageal squamous cell carcinoma compared to standard treatments.
Common Side Effects
Include anaemia, leukopenia, neutropenia, thrombocytopenia, nausea, vomiting, decreased appetite, rash, fatigue, abnormal liver function tests, hypothyroidism, constipation, and neuropathy.
Nasopharyngeal Carcinoma
Loqtorzi, in combination with cisplatin and gemcitabine, is recommended for adult patients with recurrent, non-operable or non-treatable by radiotherapy, or metastatic nasopharyngeal carcinoma.
Oesophageal Squamous Cell Carcinoma
Loqtorzi, combined with cisplatin and paclitaxel, is recommended for adult patients with unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma.
Loqtorzi should be prescribed and monitored by physicians experienced in cancer treatment. Detailed guidelines will be included in the summary of product characteristics, which will be published after the marketing authorisation is officially granted by the European Commission.
A summary of the positive opinion is available, though the final decision by the Commission is expected within 67 days of the CHMP’s recommendation.
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durv···【more】
Recommended：83Release date: 2026-06-01
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the r···【more】
Recommended：441Release date: 2025-12-17
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved nirap···【more】
Recommended：407Release date: 2025-12-15
The U.S. Food and Drug Administration (FDA) announced today that it has approved···【more】
Recommended：424Release date: 2025-12-10
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisoca···【more】
Recommended：411Release date: 2025-12-08
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full ap···【more】
Recommended：466Release date: 2025-12-04
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently mad···【more】
Recommended：674Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest incr···【more】
Recommended：624Release date: 2024-07-09
At a grand pharmaceutical exhibition held recently in Dubai, Lucius Company of L···【more】
Recommended：581Release date: 2024-07-09
On October 18-19, 2023, Dr. Luís Meirinhos Soares, a microbiology expert appoint···【more】
Recommended：576Release date: 2024-07-09
On October 19, 2023, the World Health Organization (WHO) conducted a comprehensi···【more】
Recommended：706Release date: 2024-07-09
At present, the competition in all walks of life is very fierce, especially in t···【more】
Recommended：514Release date: 2024-07-09
Here are some key points about Lucius Pharmaceutical:Lucius Pharmaceuticals has ···【more】
Recommended：740Release date: 2024-07-09
From the Black Sea, the most terrifying ocean on earth, to the Mediterranean Sea···【more】
Recommended：529Release date: 2024-07-09
Telegram name: Vira
Name: LUCIUS
No.:0085253923643
